Tenaya Therapeutics reports stockholder votes from 2022 annual meeting

Tenaya Therapeutics, Inc.

Four Class I directors elected: David Goeddel (34,063,079 for), Karah Parschauer (34,833,578), Jeffrey Walsh (34,112,810), R. Sanders Williams (34,135,556); 829,857 broker non-votes each.
Ratification of Deloitte & Touche as independent auditor for FY2022: 35,984,423 for, 148 against, 244 abstain; no broker non-votes.
All director nominees will serve until the 2025 annual meeting or until successors are elected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.